There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Regulus (RGLS – Research Report), Anavex Life Sciences (AVXL – Research Report) and Apellis Pharmaceuticals (APLS – Research Report) with bullish sentiments. Regulus (RGLS) H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Regulus today and set a price target of $20.00. The company's shares closed last Monday at $2.10, close to its 52-week low of $1.58. According to TipRanks.com, Selvaraju is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of 1.0% and a 38.9% success rate.
https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-regulus-rgls-anavex-life-sciences-avxl-and-apellis-pharmaceuticals-apls?utm_source=advfn.com&utm_medium=referral
Regulus Therapeutics (NASDAQ:RGLS)
Historical Stock Chart
From Aug 2022 to Sep 2022 Click Here for more Regulus Therapeutics Charts.
Regulus Therapeutics (NASDAQ:RGLS)
Historical Stock Chart
From Sep 2021 to Sep 2022 Click Here for more Regulus Therapeutics Charts.